CATAFLAM 50 Milligram Coated Tablets

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
06-12-2016
제품 특성 요약 제품 특성 요약 (SPC)
24-02-2018

유효 성분:

DICLOFENAC POTASSIUM

제공처:

Novartis Pharmaceuticals UK Ltd

ATC 코드:

M01AB05

INN (International Name):

DICLOFENAC POTASSIUM

복용량:

50 Milligram

약제 형태:

Coated Tablets

처방전 유형:

Product subject to prescription which may be renewed (B)

치료 영역:

Acetic acid derivatives and related substances

승인 상태:

Authorised

승인 날짜:

1995-03-13

제품 특성 요약

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Cataflam 50mg Coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50mg diclofenac potassium.
Each tablet also contains 67mg sucrose.
For a full list of excipients, see section 6.1_._
3 PHARMACEUTICAL FORM
Coated tablet (Tablet)
Circular, biconvex, reddish brown sugar coated tablets approximately
8.8mm diameter.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Short-term treatment of all grades of pain and inflammation in the
following acute conditions:
Post-traumatic pain, inflammation and swelling, e.g. due to sprains.
Acute musculo-skeletal disorders such as periarthritis (for example
frozen shoulder), tendonitis, tenosynovitis,
bursitis.
Post operative pain, inflammation and swelling, e.g. following dental
or orthopaedic surgery.
Painful and/or inflammatory conditions in gynaecology, e.g. primary
dysmenorrhoea or adnexitis and associated
menorrhagia.
Migraine attacks.
Acute gout
Painful syndromes of the vertebral column.
Non-articular rheumatism.
As an adjuvant in severe painful inflammatory infections of the ear,
nose or throat, e.g. pharyngotonsillitis, otitis.
In keeping with general therapeutic principles, the underlying disease
should be treated with basic therapy, as
appropriate. Fever alone is not an indication.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Undesirable effects may be minimised by using the lowest effective
dose for the shortest
duration necessary to control
symptoms (see section 4.4).
The tablets should be swallowed whole with liquid, preferably before
meals, and must not be divided or chewed.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___

                                
                                전체 문서 읽기